Minimal change nephrotic syndrome in children with intrauterine growth retardation.
It has been well established that intrauterine growth retardation (IUGR) is associated with greater morbidity and mortality rates during perinatal and adult life. The aim of this study is to clarify whether IUGR, defined as a birth weight less than the 10th percentile for gestational age, influences the clinical course of minimal change nephrotic syndrome (MCNS) in children. The study included 50 children aged 1 to 13 years at the onset of MCNS. The diagnosis of MCNS was confirmed by renal biopsy in 25 children (50%). Eight children (16%) had IUGR at birth. Comparisons between children with and without IUGR showed significant differences in mean number of relapses (13.0 +/- 3.5 versus 3.4 +/- 3.0 relapses; P < 0.0001) and relapse rates (relapses per year, 1.6 +/- 0.3 versus 0.5 +/- 0.4; P < 0.0001). We also observed a greater incidence of steroid dependence (100% versus 21.4%; P < 0.001) in children with than without IUGR. In addition, children with IUGR underwent treatment with cytotoxic agents and cyclosporine more frequently than those without IUGR. There was a significantly greater incidence of complications and concomitant diseases of nephrotic syndrome in children with IUGR; results show that MCNS in children with IUGR had a more unfavorable course and outcome. It is important for clinicians to be aware that IUGR may help in the early identification of children at greater risk for frequent relapses and the development of steroid dependence and/or steroid resistance. More aggressive therapy may be indicated for these children.
Sheu
J N
JN
Department of Pediatrics, Division of Pediatric Nephrology, Chung Shan Medical and Dental College Hospital, Taichung, Taiwan, Republic of China. jimsheu@csh.org.tw
Chen
J H
JH
D000284:Administration, Oral; D000293:Adolescent; D017668:Age of Onset; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D005317:Fetal Growth Retardation / Q000150:complications*; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D008297:Male; D009402:Nephrosis, Lipoid / Q000188:drug therapy / Q000209:etiology*; D011239:Prednisolone / Q000627:therapeutic use; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies
D000893:Anti-Inflammatory Agents; D011239:Prednisolone